<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435990</url>
  </required_header>
  <id_info>
    <org_study_id>MM09-SIT-023</org_study_id>
    <secondary_id>2018-004262-34</secondary_id>
    <nct_id>NCT04435990</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites</brief_title>
  <acronym>MM09-SIT-023</acronym>
  <official_title>Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SIC in Subjects With Mild/Moderate Asthma and Rhinitis/Rhinoconjunctivitis Sensitized to D.Pteronyssinus and/or D. Farinae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active&#xD;
      treatment groups, compared to 1 placebo group, for the determination of the efficacy and&#xD;
      safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with mild&#xD;
      to moderate asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides&#xD;
      farinae.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, multicenter, parallel placebo controlled study. It includes 150 subjects&#xD;
      sensitised to mites, from 14 to 65 years of age. Medication treatment of 1 year. The main&#xD;
      outcome: CSMS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, multi centre, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.&#xD;
The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.&#xD;
So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CSMS: Combined Symptoms and Medication Score</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the number of symptoms and the consumption of medication necessary for the control of such symptoms in asthma and rhinitis / rhinoconjunctivitis of each subject during the trial, of the groups with each other and with respect to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication-free days</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days that the subjects need no medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-free days</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days that the subjects have no symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by MM09-SIT-023</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with asthma</measure>
    <time_frame>12 months</time_frame>
    <description>The quality of life associated with asthma will be measured following the GINA questionnaire.&#xD;
The GINA questionnaire consists of 4 questions. In questions 1-4, patients recall their experience during the last 4 weeks and answer using YES or NO.&#xD;
The interpretation of the answers is as follows:&#xD;
Well-controlled: None of the answers are YES Partly controlled: 1 - 2 answers are YES Uncontrolled: 3-4 answers are YES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with rhinitis</measure>
    <time_frame>12 months</time_frame>
    <description>The quality of life associated with rhinitis will be measured following the test ESPRINT-15.&#xD;
The scoring of the questionnaire will be carried out as follows: The global sum of the scores (ranging from &quot;0 = nothing has bothered me&quot; to &quot;6 = it has bothered me a lot&quot;) of the 14 items plus the score given in the general questionnaire (ranging from &quot;0 = Excellent&quot; to &quot;4 = Bad&quot;). This sum is divided by the total number of items (15 items).&#xD;
The interpretation of the scores is between 0 (low impact) and 6 (high impact).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Analogue Scale in which the subject has to indicate how he/she feels regarding to his allergy symptoms at the moment from 1 to 10. Being 1 very bad and 10 very well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Analyses of total Ig3 and specific IgA,IgG and IgG4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Asthma, Allergic</condition>
  <arm_group>
    <arm_group_label>Experimental:10,000 MM09</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 TU/mL of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: 30,000 MM09</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30,000 TU/mL of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same solution and presentation as the active treatment, but without any active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10,000 MM09</intervention_name>
    <description>Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL</description>
    <arm_group_label>Experimental:10,000 MM09</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30,000 MM09</intervention_name>
    <description>Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL</description>
    <arm_group_label>Experimental: 30,000 MM09</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo subcutaneous</intervention_name>
    <description>The same solution and presentation as the active treatment, but without active ingredients.</description>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Age between 14 and 65, both genders.&#xD;
&#xD;
          -  Positive suggestive clinical history of intermittent or persistent moderate to severe&#xD;
             rhinitis /rhinoconjunctivitis, with or without moderate intermittent or persistent&#xD;
             asthma, due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae.&#xD;
&#xD;
          -  Subjects with a positive skin prick-test (wheal sixe &gt;5 mm diameter). The positive and&#xD;
             negative control of the test should give consistent results and whose determination&#xD;
             does not exceed 1 year prior to the baseline visit.&#xD;
&#xD;
          -  Specific immunoglobulin E against house dust mites &gt;3 ku/mL (InmunoCAPÂ® o Immulite),&#xD;
             for the complete extract of Dermatophagoides pteronyssinus and / or for&#xD;
             Dermatophagoides farinae or for some of the molecular components of these allergenic&#xD;
             sources and whose determination does not exceed 1 year prior to the inclusion visit.&#xD;
&#xD;
          -  Women of childbearing age (from menarche) must present a urine pregnancy test with a&#xD;
             negative result at the time of joining the trial.&#xD;
&#xD;
          -  Women of childbearing age, and men who participate in the trial, must commit to using&#xD;
             an appropriate contraceptive method, understood as any act, device or medication to&#xD;
             prevent a viable conception or pregnancy, during the trial if they are sexually&#xD;
             active.&#xD;
&#xD;
          -  Subjects with a diagnosis of asthmatic pathology made by means of a bronchodilator&#xD;
             test or subjects with a previous diagnosis of asthma according to the GEMA 5.0&#xD;
             guideline due to clinical history.&#xD;
&#xD;
          -  Subjects capable of complying with the dosing regimen.&#xD;
&#xD;
          -  Subjects who own an smartphone for symptom registration and medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects outside of the age range.&#xD;
&#xD;
          -  Subjects polysensitized to other aeroallergens in addition to Dermatophagoides&#xD;
             pteronyssinus and Dermatophagoides farinae, except for epithelia with exposure and&#xD;
             occasional symptoms.&#xD;
&#xD;
          -  Subjects who have received prior immunotherapy in the preceding 5 years for any of the&#xD;
             allergens tested or an allergen with cross-reactivity or are currently receiving&#xD;
             immunotherapy with any allergen.&#xD;
&#xD;
          -  Subjects in which immunotherapy may be subject to an absolute general contraindication&#xD;
             according to the criteria of the Immunotherapy Committee of the Spanish Society of&#xD;
             Allergy and Clinical Immunology and the European Allergy and Clinical Immunology&#xD;
             Immunotherapy Subcommittee.&#xD;
&#xD;
          -  Subjects have not granted written informed consent.&#xD;
&#xD;
          -  Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1&#xD;
             &lt;70% with respect to the reference value despite adequate pharmacological treatment at&#xD;
             the time of inclusion in the trial. Likewise, subjects with intermittent or persistent&#xD;
             rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or&#xD;
             systemic antihistamine treatment is contraindicated.&#xD;
&#xD;
          -  Subjects who required oral corticosteroids in the 12 weeks prior to enrollment in the&#xD;
             trial.&#xD;
&#xD;
          -  Subjects who have previously presented a serious secondary reaction during the&#xD;
             performance of diagnostic skin tests using the prick test.&#xD;
&#xD;
          -  Subjects under treatment with Î²-blockers.&#xD;
&#xD;
          -  Clinically unstable subjects at the time of inclusion in the trial (acute asthma&#xD;
             exacerbation, respiratory infection, feverish process, acute urticaria, etc.).&#xD;
&#xD;
          -  Subjects with active chronic urticaria, severe dermography, severe atopic dermatitis,&#xD;
             sunburn, active psoriasis with lesions in areas where skin tests are performed, or a&#xD;
             history of hereditary angioedema.&#xD;
&#xD;
          -  Subjects that have some pathology in which the administration of adrenaline is&#xD;
             contraindicated (hyperthyroidism, hypertension, heart disease, etc.).&#xD;
&#xD;
          -  Subjects with some other disease not related to moderate rhinoconjunctivitis or&#xD;
             asthma, but of potential severity and that may interfere with treatment and follow-up&#xD;
             (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple&#xD;
             operations, kidney disease,).&#xD;
&#xD;
          -  Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a&#xD;
             diagnosis of immunodeficiencies.&#xD;
&#xD;
          -  Subject whose status prevents him from offering cooperation and or who has severe&#xD;
             psychiatric disorders.&#xD;
&#xD;
          -  Subjects with a known allergy to other components of the investigational medicinal&#xD;
             product other than the allergen.&#xD;
&#xD;
          -  Subjects with diseases of the lower respiratory tract other than asthma such as&#xD;
             emphysema or bronchiectasis.&#xD;
&#xD;
          -  Direct investigator's relatives.&#xD;
&#xD;
          -  Pregnant or women at risk of pregnancy and breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Pujadas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>QuirÃ³n Palma de Mallorca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Tubella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cenvi Medic, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Malet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergocentre, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Ãngel AÃ±Ã³, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alergocantabria, Santander</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel HerrÃ­as, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Privada Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio LetrÃ¡n, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital HLA JerÃ©z Puerta del Sur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego GutiÃ©rrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClÃ­nica Virgen del Rosario, Algeciras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica QuirÃ³n Salud, CÃ³rdoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel BarcelÃ³, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Privada, MÃ¡laga.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MÂº JosÃ© Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro MÃ©dico Puerto, Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabella RaducÃ¡n, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClÃ­nica TECMA, Alzira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noelia Colomer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClÃ­nica IMED, Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugenia Margarita Campos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClÃ­nica IMED, Elche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CÃ©sar AlÃ­as, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClÃ­nica Corachan, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JoaquÃ­n MartÃ­n, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital POLUSA, Lugo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Moreno, MD</last_name>
    <phone>956292100</phone>
    <phone_ext>+34</phone_ext>
    <email>dr.moreno@drlobaton.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, MD PhD</last_name>
    <phone>916510010</phone>
    <phone_ext>+34</phone_ext>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eugenia Margarita Campos</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Margarita Campos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Virgen del Rosario</name>
      <address>
        <city>Algeciras</city>
        <state>Cadiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego GutiÃ©rrez FernÃ¡ndez, MD</last_name>
      <phone>956 09 04 93</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergocenter</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Malet</last_name>
      <phone>932 90 62 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro privado Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar AlÃ­as</last_name>
      <phone>670393166</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cenvi Medic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Tubella MartÃ­n, MD</last_name>
      <phone>935047100</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CÃ©sar AlÃ­as</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica privada</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Herrerias, MD</last_name>
      <phone>609855985</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro MÃ©dico ASISA Dr. LobatÃ³n</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Moreno, MD</last_name>
      <phone>956407298</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro mÃ©dico puerto</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MÂº JosÃ© Pereira GonzÃ¡lez</last_name>
      <phone>956 85 10 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Salud CÃ³rdoba</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Garcia NÃºÃ±ez</last_name>
      <phone>956 79 83 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital HLA Jerez Puerta Sur</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio LetrÃ¡n Camacho, MD</last_name>
      <phone>956 35 71 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>JoaquÃ­n MartÃ­n</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica privada</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel BarcelÃ³ MuÃ±oz, MD</last_name>
      <email>informaciÃ³n@doctorbarcelo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QuirÃ³n</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pujadas, MD</last_name>
      <phone>971 91 80 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alergocantabria</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Ãngel AÃ±Ã³, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica IMED</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelia Colomer, MD</last_name>
      <phone>963 00 30 00</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Tecma Alzira</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Raducan, MD</last_name>
      <phone>962 45 58 92</phone>
      <phone_ext>+34</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Piacentini GL, Vicentini L, Mazzi P, Chilosi M, Martinati L, Boner AL. Mite-antigen avoidance can reduce bronchial epithelial shedding in allergic asthmatic children. Clin Exp Allergy. 1998 May;28(5):561-7.</citation>
    <PMID>9645592</PMID>
  </reference>
  <reference>
    <citation>Yepes-NÃºÃ±ez JJ, GÃ³mez C, Espinoza Y, Cardona R. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma]. Biomedica. 2014 Apr-Jun;34(2):282-90. doi: 10.1590/S0120-41572014000200014. Spanish.</citation>
    <PMID>24967933</PMID>
  </reference>
  <reference>
    <citation>Cardona R, Lopez E, BeltrÃ¡n J, SÃ¡nchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014 Mar-Apr;42(2):90-5. doi: 10.1016/j.aller.2012.07.005. Epub 2012 Dec 20.</citation>
    <PMID>23265265</PMID>
  </reference>
  <reference>
    <citation>Bousquet J, Hejjaoui A, Clauzel AM, GuÃ©rin B, Dhivert H, Skassa-Brociek W, Michel FB. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol. 1988 Dec;82(6):971-7.</citation>
    <PMID>3204255</PMID>
  </reference>
  <reference>
    <citation>Branco Ferreira M, SpÃ­nola Santos A, Pereira Santos MC, Palma Carlos ML, Pereira Barbosa MA, Palma Carlos AG. Efficacy and safety of specific immunotherapy with a modified mite extract. Allergol Immunopathol (Madr). 2005 Mar-Apr;33(2):80-5.</citation>
    <PMID>15808114</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis/ Rhinoconjunctivitis</keyword>
  <keyword>Mild to moderate asthma</keyword>
  <keyword>Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Mites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

